Protocol Ledger

NCT06502977 · Phase II · ACTIVE NOT RECRUITING

Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment

Interventional Phase II clinical trial protocol NCT06502977 sponsored by Amgen in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-08-27 Enrollment: 32 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06502977
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)32 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06502977
Protocol FieldVerified Registry Value
NCT IdentifierNCT06502977
Consolidated Lead SponsorAmgen
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment32 participants (ACTUAL)
Registered Start Date2024-08-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI